Wave Life Sciences (WVE) Amortization of Deferred Charges (2019 - 2025)
Wave Life Sciences' Amortization of Deferred Charges history spans 7 years, with the latest figure at $1.4 million for Q4 2025.
- For Q4 2025, Amortization of Deferred Charges rose 13.53% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.4 million, up 13.53%, while the annual FY2025 figure was $5.4 million, 13.53% up from the prior year.
- Amortization of Deferred Charges reached $1.4 million in Q4 2025 per WVE's latest filing, up from $1.4 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q4 2025 to a low of $512000.0 in Q1 2021.
- Average Amortization of Deferred Charges over 5 years is $1.0 million, with a median of $1.0 million recorded in 2023.
- Peak YoY movement for Amortization of Deferred Charges: surged 75.27% in 2022, then increased 10.68% in 2023.
- A 5-year view of Amortization of Deferred Charges shows it stood at $759000.0 in 2021, then increased by 29.51% to $983000.0 in 2022, then grew by 12.0% to $1.1 million in 2023, then rose by 13.44% to $1.2 million in 2024, then rose by 13.53% to $1.4 million in 2025.
- Per Business Quant, the three most recent readings for WVE's Amortization of Deferred Charges are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.3 million (Q2 2025).